C12Y 301/21
Endodeoxyribonucleases producing 5'-phosphomonoesters
Official title: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
C12Y301/21 (Endodeoxyribonucleases producing 5'-phosphomonoesters) appears on 349 US grants and 692 published applications in this corpus.
Search patents in C12Y- Granted patents
- 349
- Published applications
- 692
- Assignees
- 241
- Inventors
- 768
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 0 |
| 2003 | 0 | 3 |
| 2004 | 0 | 1 |
| 2005 | 1 | 1 |
| 2006 | 1 | 5 |
| 2007 | 0 | 2 |
| 2008 | 1 | 2 |
| 2009 | 1 | 4 |
| 2010 | 1 | 9 |
| 2011 | 1 | 10 |
| 2012 | 3 | 18 |
| 2013 | 11 | 13 |
| 2014 | 17 | 37 |
| 2015 | 12 | 32 |
| 2016 | 25 | 50 |
| 2017 | 23 | 44 |
| 2018 | 20 | 53 |
| 2019 | 30 | 55 |
| 2020 | 37 | 56 |
| 2021 | 25 | 45 |
| 2022 | 37 | 47 |
| 2023 | 29 | 44 |
| 2024 | 22 | 50 |
| 2025 | 22 | 52 |
| 2026 | 21 | 59 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 301/21001Deoxyribonuclease i136
- C12Y 301/21004Type ii site-specific deoxyribonuclease135
- C12Y 301/21007Deoxyribonuclease v7
- C12Y 301/21002Deoxyribonuclease iv5
- C12Y 301/21003Type i site-specific deoxyribonuclease4
- C12Y 301/21005Type iii site-specific deoxyribonuclease3
- C12Y 301/21006Cc-preferring endodeoxyribonuclease0
Recent patents
- Compositions comprising a CAS12I polypeptide and uses thereof29 Sep 2026US 12,747,457 B2Arbor Biotechnologies, Inc.
- Polypeptide variants29 Sep 2026US RE51,046 E1Novozymes A/S
- Enzymes with RUVC domains15 Sep 2026US 12,735,688 B2Metagenomi Therapeutics, Inc.
- Engineered cells secreting therapeutic enzymes18 Aug 2026US 12,709,739 B2Cartesian Therapeutics, Inc.
- Therapeutic circular DNA forms21 Jul 2026US 12,685,745 B2Flagship Pioneering Innovations Vii, LLC
- Therapeutic circular dna forms1 Oct 2026US 2026/0294957 A1Flagship Pioneering Innovations Vii, LLC
- Producing Engineered Cells by Introducing Cas9/sgRNA Complexes17 Sep 2026US 2026/0275358 A1Toolgen Incorporated
- Producing Engineered Cells by Introducing Cas9/sgRNA Complexes27 Aug 2026US 2026/0250690 A1Toolgen Incorporated
- Mutated v-type crispr enzyme and use thereof27 Aug 2026US 2026/0250744 A1Beijing Synsorbio Technology Co., Ltd.
- Fusion proteins and applications thereof20 Aug 2026US 2026/0242761 A1Guangzhou Reforgene Medicine Co., Ltd.
Most cited
By later US patents
- DNA-binding proteins and uses thereof217US 8,586,526 B2Sangamo BioSciences, Inc. · 2013
- TAL effector-mediated DNA modification216US 8,440,431 B2Iowa State University Research Foundation, Inc. · 2013
- Tal effector-mediated DNA modification187US 8,440,432 B2Iowa State University Research Foundation, Inc. · 2013
- TAL effector-mediated DNA modification186US 8,450,471 B2Iowa State University Research Foundation, Inc. · 2013
- Methods and compositions for targeted cleavage and recombination184US 7,888,121 B2Sangamo BioSciences, Inc. · 2011